Bivalirudin
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00006 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 14 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | primary release disorder of platelets | KG + DL |
| 2 | Glanzmann thrombasthenia | KG + DL |
| 3 | pseudo-von Willebrand disease | KG + DL |
| 4 | rheumatoid arthritis | KG + DL |
| 5 | bleeding diathesis due to a collagen receptor defect | KG + DL |
| 6 | hemorrhagic disorder due to a constitutional thrombocytopenia | KG + DL |
| 7 | fetal and neonatal alloimmune thrombocytopenia | KG + DL |
| 8 | Scott syndrome | KG + DL |
| 9 | inherited thrombophilia | KG + DL |
| 10 | platelet-type bleeding disorder | KG + DL |
| 11 | thrombotic thrombocytopenic purpura | KG + DL |
| 12 | gout | KG + DL |
| 13 | autosomal dominant macrothrombocytopenia | KG + DL |
| 14 | thrombocytopenic purpura | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.